Seelos Therapeutics to Participate in the B. Riley Securities' Virtual Neuro and Ophthalmology Conference

Rhea-AI Summary

Seelos Therapeutics (Nasdaq: SEEL), a clinical-stage biopharmaceutical firm, will participate in the B. Riley Securities' Virtual Neuro and Ophthalmology Conference on April 27-28, 2022. The event will feature a fireside chat with Raj Mehra, Ph.D., and Tim Whitaker, MD, on April 27 at 12:00 PM ET. Seelos is dedicated to developing therapies for central nervous system disorders and other rare diseases, with a portfolio targeting conditions such as Acute Suicidal Ideation in Major Depressive Disorder, ALS, and Parkinson's disease.

NEW YORK, April 22, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the B. Riley Securities' Virtual Neuro and Ophthalmology Conference, April 27-28, 2022.

Raj Mehra, Ph.D., Chairman and CEO and Tim Whitaker, MD, Chief Medical Officer, will participate in a fireside chat on Wednesday, April 27^th at 12:00 PM ET.

For registration: B. Riley Securities' Virtual Neuro and Ophthalmology Conference

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD), amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA), Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Contact Information:

Anthony Marciano
Chief Communications Officer
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue, 2^nd Floor
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

Mike Moyer Managing Director
LifeSci Advisors, LLC
250 West 55th St., Suite 3401 
New York, NY 10019
(617) 308-4306
mmoyer@lifesciadvisors.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-the-b-riley-securities-virtual-neuro-and-ophthalmology-conference-301530956.html

SOURCE Seelos Therapeutics, Inc.

FAQ

What conference will Seelos Therapeutics participate in?

Seelos Therapeutics will participate in the B. Riley Securities' Virtual Neuro and Ophthalmology Conference on April 27-28, 2022.

When is the fireside chat with Seelos Therapeutics' executives?

The fireside chat featuring Raj Mehra and Tim Whitaker is scheduled for April 27, 2022, at 12:00 PM ET.

What is Seelos Therapeutics focused on developing?

Seelos Therapeutics is focused on developing therapies for central nervous system disorders and rare diseases.

What are some conditions targeted by Seelos Therapeutics?

Seelos Therapeutics targets conditions such as Acute Suicidal Ideation in Major Depressive Disorder, ALS, and Parkinson's disease.

How can I register for the B. Riley Securities conference?

You can register for the conference through the provided link in the press release.